Karakiewicz Pierre I, Shariat Shahrokh F, Palapattu Ganesh S, Gilad Amiel E, Lotan Yair, Rogers Craig G, Vazina Amnon, Gupta Amit, Bastian Patrick J, Perrotte Paul, Sagalowsky Arthur I, Schoenberg Mark, Lerner Seth P
Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada.
J Urol. 2006 Oct;176(4 Pt 1):1354-61; discussion 1361-2. doi: 10.1016/j.juro.2006.06.025.
American Joint Committee on Cancer staging represents the gold standard for prediction of recurrence after radical cystectomy in patients with invasive bladder cancer. We tested the hypothesis that American Joint Committee on Cancer stage based predictions may be improved when pathological tumor and node stage information is combined with additional clinical and pathological variables within a prognostic nomogram.
We used Cox proportional hazards regression analysis to model variables of 728 patients with transitional cell carcinoma of the bladder treated with radical cystectomy and bilateral pelvic lymphadenectomy at 1 of 3 participating institutions. Standard predictors, pT and pN, were complemented by age, gender, tumor grade at cystectomy, presence of lymphovascular invasion, presence of carcinoma in situ in the cystectomy specimen, neoadjuvant chemotherapy, adjuvant chemotherapy and adjuvant radiotherapy. The concordance index was used to quantify the accuracy of regression coefficient based nomograms. A total of 200 bootstrap resamples were used to reduce overfit bias and for internal validation. Calibration plots were used to graphically explore the performance characteristics of the multivariate nomogram.
Followup ranged from 0.1 to 183.4 months (median 24.9, mean 36.4). Recurrence was recorded in 249 (34.2%) patients with a median time to recurrence of 108 months (range 0.8 to 131.9). Actuarial recurrence-free probabilities were 69.6% (95% CI 65.8%-73.0%), 60.2% (55.8%-64.3%) and 52.9% (47.3%-58.1%) at 2, 5 and 8 years after cystectomy, respectively. Two-hundred bootstrap corrected predictive accuracy of American Joint Committee on Cancer stage based predictions was 0.748. Accuracy increased by 3.2% (0.780) when age, lymphovascular invasion, carcinoma in situ, neoadjuvant chemotherapy, adjuvant chemotherapy and adjuvant radiotherapy were added to pathological stage information and used within a nomogram.
A nomogram predicting bladder cancer recurrence after cystectomy is 3.2% more accurate than American Joint Committee on Cancer stage based predictions. Moreover, a nomogram approach combines several advantages such as easy and precise estimation of individual recurrence probability at key points after cystectomy, which all patients deserve to know and all treating physicians need to know.
美国癌症联合委员会(AJCC)分期是预测浸润性膀胱癌患者根治性膀胱切除术后复发的金标准。我们检验了这样一个假设:当将病理肿瘤和淋巴结分期信息与预后列线图中的其他临床和病理变量相结合时,基于美国癌症联合委员会分期的预测可能会得到改善。
我们使用Cox比例风险回归分析对在3个参与机构之一接受根治性膀胱切除术和双侧盆腔淋巴结清扫术的728例膀胱移行细胞癌患者的变量进行建模。标准预测指标pT和pN由年龄、性别、膀胱切除时的肿瘤分级、淋巴管浸润情况、膀胱切除标本中原位癌的存在情况、新辅助化疗、辅助化疗和辅助放疗进行补充。一致性指数用于量化基于回归系数的列线图的准确性。共使用200次自抽样重采样来减少过度拟合偏差并进行内部验证。校准图用于以图形方式探索多变量列线图的性能特征。
随访时间为0.1至183.4个月(中位时间24.9个月,平均36.4个月)。249例(34.2%)患者出现复发,复发的中位时间为108个月(范围0.8至131.9个月)。膀胱切除术后2年、5年和8年的无复发生存概率分别为69.6%(95%CI 65.8%-73.0%)、60.2%(55.8%-64.3%)和52.9%(47.3%-58.1%)。基于美国癌症联合委员会分期的预测经200次自抽样校正后的预测准确性为0.748。当将年龄、淋巴管浸润、原位癌、新辅助化疗、辅助化疗和辅助放疗添加到病理分期信息中并用于列线图时,准确性提高了3.2%(0.780)。
预测膀胱切除术后膀胱癌复发的列线图比基于美国癌症联合委员会分期的预测准确性高3.2%。此外,列线图方法具有几个优点,例如可以轻松、精确地估计膀胱切除术后关键点的个体复发概率,这是所有患者都应该知道且所有治疗医生都需要了解的。